Literature DB >> 15179000

Strategies and clinical implications of chimerism diagnostics after allogeneic hematopoietic stem cell transplantation.

Christian Thiede1, Martin Bornhäuser, Gerhard Ehninger.   

Abstract

Analysis of donor chimerism has become a routine method for the documentation of engraftment after allogeneic hematopoietic stem cell transplantation (HSCT). In recent years several groups have also focused on the application of this technique for the detection of relapsing disease after allogeneic HSCT. This review addresses technical issues (sensitivity, specificity) and discusses the advantages and limitations of methods currently used for chimerism analysis and their usefulness for the detection of MRD. In addition, the potential impact of novel procedures, e.g. subset chimerism or real-time PCR-based procedures, is discussed. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2004        PMID: 15179000     DOI: 10.1159/000077555

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  14 in total

1.  Diagnostic molecular pathology, part 2: proteomics and clinical applications of molecular diagnostics in hematopathology.

Authors:  Georges J Netto; Rana Saad
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-01

2.  Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  Hans C Lee; Rima M Saliba; Gabriela Rondon; Julianne Chen; Yasmeen Charafeddine; L Jeffrey Medeiros; Gheath Alatrash; Borje S Andersson; Uday Popat; Partow Kebriaei; Stefan Ciurea; Betul Oran; Elizabeth Shpall; Richard Champlin
Journal:  Biol Blood Marrow Transplant       Date:  2015-07-14       Impact factor: 5.742

3.  Validation of chimerism in pediatric recipients of allogeneic hematopoietic stem cell transplantation (HSCT) a comparison between two methods: real-time PCR (qPCR) vs. variable number tandem repeats PCR (VNTR PCR).

Authors:  Morris Kletzel; Wei Huang; Marie Olszewski; Sana Khan
Journal:  Chimerism       Date:  2012-12-13

4.  Mixed myeloid chimerism and relapse of myelofibrosis after allogeneic stem cell transplantation.

Authors:  Samer A Srour; Amanda Olson; Stefan O Ciurea; Parth Desai; Qaiser Bashir; Betul Oran; Prithviraj Bose; Rohtesh Mehta; Keyur P Patel; Naveen Pemmaraju; Naval Daver; Srdan Verstovsek; Richard E Champlin; Uday R Popat
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

5.  Feasibility of salvage cord blood transplantation using a fludarabine, melphalan, and low-dose anti-thymocyte globulin conditioning regimen.

Authors:  Takumi Hoshino; Satoru Takada; Nahoko Hatsumi; Toru Sakura
Journal:  Int J Hematol       Date:  2019-02-08       Impact factor: 2.490

Review 6.  Beyond chimerism analysis: methods for tracking a new generation of cell-based medicines.

Authors:  Joaquim Vives; Aina Casademont-Roca; Lluís Martorell; Núria Nogués
Journal:  Bone Marrow Transplant       Date:  2020-02-05       Impact factor: 5.483

7.  Bone marrow engraftment analysis after granulocyte transfusion.

Authors:  Sharon L Swierczynski; Michael J Hafez; Juliet Philips; Meghan A Higman; Karin D Berg; Kathleen M Murphy
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

8.  Analysis of hematopoietic stem cell transplant engraftment: use of loss or gain of microsatellite alleles to identify residual hematopoietic malignancy.

Authors:  Ming-Tseh Lin; Li-Hui Tseng; Katie Beierl; Shuko Harada; Michael J Hafez; James R Eshleman; Christopher D Gocke
Journal:  Diagn Mol Pathol       Date:  2011-12

9.  5-azacytidine as salvage treatment in relapsed myeloid tumors after allogeneic bone marrow transplantation.

Authors:  Javier Bolaños-Meade; B Douglas Smith; Steven D Gore; Michael A McDevitt; Leo Luznik; Ephraim J Fuchs; Richard J Jones
Journal:  Biol Blood Marrow Transplant       Date:  2010-10-15       Impact factor: 5.742

10.  Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial.

Authors:  U Platzbecker; M Wermke; J Radke; U Oelschlaegel; F Seltmann; A Kiani; I-M Klut; H Knoth; C Röllig; J Schetelig; B Mohr; X Graehlert; G Ehninger; M Bornhäuser; C Thiede
Journal:  Leukemia       Date:  2011-09-02       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.